Mechanism and kinetics study of MG1113, an anti-tissue factor pathway inhibitor antibody promoting hemostasis in hemophilia

Background Targeting tissue factor pathway inhibitor (TFPI) is an emerging hemostatic rebalancing strategy for hemophilia. MG1113 is a humanized monoclonal antibody designed to specifically bind the Kunitz domain 2 (KD2) of TFPI. Objectives To elucidate the detailed pharmacological mechanism of action and the preclinical hemostatic efficacy of MG1113. Methods In vivo efficacy was evaluated using an acquired hemophilia A (HA) cynomolgus monkey model. In vitro chromogenic assays, factor Xa (FXa) generation, and clot waveform analysis (CWA) were performed in human factor-deficient plasmas to assess the dynamics of coagulation. Additionally, a cell-based system utilizing EA.hy926 endothelial cells was established to examine the dual neutralization of TFPI isoforms. Results In acquired HA monkeys, a single dose of MG1113 (3 mg/kg) reduced free TFPI levels by 98.8%, shortened the modified prothrombin time, and restored thrombin peak height to approximately 78% of normal levels. Mechanistically, MG1113 successfully prevented TFPI-mediated inhibition of the extrinsic tenase complex—specifically in the presence of FXa—despite targeting only KD2. MG1113 restored the FXa amplification loop and simultaneously neutralized both plasma-derived TFPI-α and cell-surface TFPI-β. However, despite sufficiently restoring FXa generation, CWA revealed that MG1113 exhibited a broader, less intense, and more prolonged coagulation profile compared to the rapid burst characteristic of factor replacement therapy. Conclusions MG1113 effectively restores hemostasis by blocking the TFPI/FXa interaction. By systematically lowering the threshold for tissue factor-mediated initiation, MG1113 facilitates physiological restoration of hemostasis. This mechanistic profile—combined with gradual clot kinetics and the advantages of a monoclonal antibody—makes MG1113 suited for routine prophylaxis.